Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

Mirati – which is expecting a verdict on adagrasib from the FDA in December - also said the disease control rate was 80% with adagrasib, while the median duration of response came in at 8.5 ...